These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 15875186)

  • 1. Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2).
    Mohrmann K; van Eijndhoven MA; Schinkel AH; Schellens JH
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):344-50. PubMed ID: 15875186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
    Doyle L; Ross DD
    Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants.
    Miwa M; Tsukahara S; Ishikawa E; Asada S; Imai Y; Sugimoto Y
    Int J Cancer; 2003 Dec; 107(5):757-63. PubMed ID: 14566825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-Linked glycosylation of the human ABC transporter ABCG2 on asparagine 596 is not essential for expression, transport activity, or trafficking to the plasma membrane.
    Diop NK; Hrycyna CA
    Biochemistry; 2005 Apr; 44(14):5420-9. PubMed ID: 15807535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knockdown of caveolin-1 decreases activity of breast cancer resistance protein (BCRP/ABCG2) and increases chemotherapeutic sensitivity.
    Herzog M; Storch CH; Gut P; Kotlyar D; Füllekrug J; Ehehalt R; Haefeli WE; Weiss J
    Naunyn Schmiedebergs Arch Pharmacol; 2011 Jan; 383(1):1-11. PubMed ID: 20936466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro.
    Storch CH; Ehehalt R; Haefeli WE; Weiss J
    J Pharmacol Exp Ther; 2007 Oct; 323(1):257-64. PubMed ID: 17652262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).
    Shen H; Lee FY; Gan J
    J Pharmacol Exp Ther; 2011 May; 337(2):423-32. PubMed ID: 21262849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo.
    Ceckova M; Libra A; Pavek P; Nachtigal P; Brabec M; Fuchs R; Staud F
    Clin Exp Pharmacol Physiol; 2006; 33(1-2):58-65. PubMed ID: 16445700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The gut microbiota ellagic acid-derived metabolite urolithin A and its sulfate conjugate are substrates for the drug efflux transporter breast cancer resistance protein (ABCG2/BCRP).
    González-Sarrías A; Miguel V; Merino G; Lucas R; Morales JC; Tomás-Barberán F; Alvarez AI; Espín JC
    J Agric Food Chem; 2013 May; 61(18):4352-9. PubMed ID: 23586460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of basic residues within or near the predicted transmembrane helix 2 of the human breast cancer resistance protein in drug transport.
    Cai X; Bikadi Z; Ni Z; Lee EW; Wang H; Rosenberg MF; Mao Q
    J Pharmacol Exp Ther; 2010 Jun; 333(3):670-81. PubMed ID: 20203106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models.
    Breedveld P; Pluim D; Cipriani G; Dahlhaus F; van Eijndhoven MA; de Wolf CJ; Kuil A; Beijnen JH; Scheffer GL; Jansen G; Borst P; Schellens JH
    Mol Pharmacol; 2007 Jan; 71(1):240-9. PubMed ID: 17032904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
    Breedveld P; Zelcer N; Pluim D; Sönmezer O; Tibben MM; Beijnen JH; Schinkel AH; van Tellingen O; Borst P; Schellens JH
    Cancer Res; 2004 Aug; 64(16):5804-11. PubMed ID: 15313923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
    Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
    Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions of cyclosporin a with breast cancer resistance protein.
    Xia CQ; Liu N; Miwa GT; Gan LS
    Drug Metab Dispos; 2007 Apr; 35(4):576-82. PubMed ID: 17220244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytoplasmic confinement of breast cancer resistance protein (BCRP/ABCG2) as a novel mechanism of adaptation to short-term folate deprivation.
    Ifergan I; Jansen G; Assaraf YG
    Mol Pharmacol; 2005 Apr; 67(4):1349-59. PubMed ID: 15657365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative transporter proteomics by liquid chromatography with tandem mass spectrometry: addressing methodologic issues of plasma membrane isolation and expression-activity relationship.
    Kumar V; Prasad B; Patilea G; Gupta A; Salphati L; Evers R; Hop CE; Unadkat JD
    Drug Metab Dispos; 2015 Feb; 43(2):284-8. PubMed ID: 25488931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2.
    Henriksen U; Gether U; Litman T
    J Cell Sci; 2005 Apr; 118(Pt 7):1417-26. PubMed ID: 15769853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells.
    Karlsson JE; Heddle C; Rozkov A; Rotticci-Mulder J; Tuvesson O; Hilgendorf C; Andersson TB
    Drug Metab Dispos; 2010 Apr; 38(4):705-14. PubMed ID: 20071452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2).
    Merino G; Jonker JW; Wagenaar E; Pulido MM; Molina AJ; Alvarez AI; Schinkel AH
    Drug Metab Dispos; 2005 May; 33(5):614-8. PubMed ID: 15703302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.